- Conditions
- Hidradenitis Suppurativa
- Interventions
- Ertapenem
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 160
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hidradenitis Suppurativa
- Interventions
- SAR444656 (KT-474), Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • Anaheim, California • Fountain Valley, California + 17 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- anakinra
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Hidradenitis Suppurativa, Acne Inversa
- Interventions
- Brodalumab
- Drug
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hidradenitis Suppurativa, Healthy Volunteers
- Interventions
- Radiofrequency-Based treatment
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 22 Years to 70 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Wounds, Hidradenitis Suppurativa, Hidradenitis, Acne Inversa
- Interventions
- Not listed
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 743 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Laight therapy, NICE V3.1 device
- Device
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Not listed
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 400 participants
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Home Exercise Program, Short Exercise Program
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Spesolimab i.v., Spesolimab s.c., Placebo matching Spesolimab i.v., Placebo matching Spesolimab s.c.
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Fountain Valley, California • Los Angeles, California • Sacramento, California + 15 more
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Roflumilast 0.3% topical foam
- Drug
- Lead sponsor
- Harrison Dermatology
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Missouri City, Texas
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Ruxolitinib cream, Vehicle cream
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Boca Raton, Florida + 12 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Spesolimab 1200 mg, Spesolimab 600 mg, Placebo matching 600 mg Spesolimab, Placebo matching 1200 mg Spesolimab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 1 more
- Conditions
- Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
- Interventions
- Bimekizumab
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Santa Monica, California • South Miami, Florida • Boston, Massachusetts + 3 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Ritlecitinib, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 30
- States / cities
- Hot Springs, Arkansas • Fountain Valley, California • Northridge, California + 22 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Lutikizumab, Placebo
- Biological · Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 20 more
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Spesolimab, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Fountain Valley, California • Los Angeles, California • Sacramento, California + 1 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- AVTX-009 Regimen 1, AVTX-009 Regimen 2, Placebo
- Drug
- Lead sponsor
- Avalo Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 36
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Northridge, California + 31 more
- Conditions
- Atopic Dermatitis, Dermatology, Vitiligo, Alopecia Areata, Hidradenitis Suppurativa, Psoriasis
- Interventions
- N/A This is an observational study
- Other
- Lead sponsor
- OM1, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hidradenitis Suppurativa
- Interventions
- adalimumab, Placebo
- Biological · Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Bakerfield, California • Los Angeles, California + 15 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- SAR445399, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • North Hollywood, California • Boynton Beach, Florida + 16 more
- Conditions
- Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
- Interventions
- Not listed
- Lead sponsor
- Target PharmaSolutions, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,000,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2041
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hidradenitis Suppurativa, Quality of Life
- Interventions
- Mindfulness Course, HS Educational Course
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Roflumilast 0.3% topical foam
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts